JP Morgan Upgrades Pacira BioSciences to Neutral Amid Sharp Price Gain

On October 8, 2026, JP Morgan upgraded its outlook for Pacira BioSciences (NASDAQGS:PCRX) (DB:82P), revising its rating from Underweight to Neutral.

Pacira BioSciences, Inc., headquartered in the United States, operates within the pharmaceutical sector, focusing on the development, manufacture, and commercialization of non-opioid pain management and regenerative health solutions. Its flagship product, EXPAREL, is a liposome injection of bupivacaine intended to provide extended pain relief without opioids following surgical procedures.

The rating change coincides with significant market momentum. Pacira closed at $36.40 on October 8, 2026, up from $25.20 on October 7, 2026. This represents a one-week gain of 45.54% relative to the October 1 baseline close of $25.01. Over the past month, the stock has risen 40.70%, tracking from a baseline close of $25.87 on September 8, 2026.

Regarding valuation targets, the consensus mean price objective stood at $29.84 (median: $29.58) as of October 2, 2026. This implies an 18.04% downside from the current valuation. The previous consensus mean was $29.43 as of September 15, 2026, reflecting a consensus target revision of +1.36%.

Aggregate analyst sentiment remains predominantly bullish. For the recommendation period beginning September 1, 2026, there were 13 total recommendations, comprising three strong buys, six buys, three holds, and one sell. This distribution translates to 69.2% positive, 23.1% hold, and 7.7% negative ratings. In the prior period beginning August 1, 2026, there were 12 recommendations—three strong buys, five buys, three holds, and one sell—representing 66.7% positive, 25.0% hold, and 8.3% negative ratings.

Other recent analyst activity includes Truist Securities maintaining a Buy rating on October 7, 2026. Earlier, Oppenheimer initiated coverage with an Outperform rating on September 23, 2026, followed by Leerink Partners initiating coverage with a Market Perform rating on September 9, 2026.

In its most recent earnings report released on August 4, 2026, Pacira BioSciences reported an EPS of $0.73, beating estimates of $0.6603 for a surprise of +10.56%. Quarterly revenue came in at $192,399,000, slightly below the estimated $194,632,728. The company is scheduled to report its next earnings on November 4, 2026.

Recent Analyst Actions

Source link